Fesoterodine Fumarate Tablet, Extended Release
Product Images NDC 67877-064

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 67877-064). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fesoterodine-4mg-1 (Fesoterodine 4mg 1)

Each tablet of ASCEnD contains 4mg of fesoterodine fumarate, and is film-coated. The usual dosage is not available, and prescribing information must be adhered to. These extended-release tablets must be stored in an unvarnished area between 15°C and 30°C, protected from moisture. They measure 45x20mm (LxH). This medication is manufactured by Alkem Laboratories Ltd. and distributed by Ascend Laboratories LLC. A patient information leaflet should be included with the package. This medication is only available via prescription.*

FDA Label Image

Fesoterodine-8mg-1 (Fesoterodine 8mg 1)

This text appears to be a combination of a description of a medication called Fesoterodine Fumarate and packaging instructions. The medication comes in a form of extended-release, film-coated tablets that contain 8mg of Fesoterodine Fumarate. The tablets should be stored between 15 and 30 degrees Celsius and protected from moisture. A pharmacist should dispense the medication with an information leaflet for the patient. The manufacturer is Alkem Laboratories Ltd. and the medication is distributed by Ascend Laboratories LLC in Parsippany, NJ.*

FDA Label Image

Fesoterodine-fig1.jpg (Fesoterodine Fig1)

FDA Label Image

Fesoterodine-fig2.jpg (Fesoterodine Fig2)

The text describes a graph or figure showing the change in urge incontinence episodes per 24 hours over the course of several weeks. The figure includes a comparison between two treatments, one labeled as "placebo" and the other as "fesoterodine fumarate." The mean change from baseline is given for each treatment. No further information is available.*

FDA Label Image

Fesoterodine-fig3.jpg (Fesoterodine Fig3)

The text is presenting a figure titled “Change in Number of Micturitions per 24 h (Study 2)”. The figure consists of a graph with the X-axis representing the weeks of the study and the Y-axis representing the number of micturitions per 24 hours. However, due to errors, the drug names and dosages cannot be accurately determined from the provided text.*

FDA Label Image

Fesoterodine-fig4.jpg (Fesoterodine Fig4)

The text includes a figure labeled "Figure 4" representing the change in Urge Incontinence Episodes per 24 h over time (Weeks 0, 2, and 8) for two groups of patients: one group receiving Fesoterodine Fumarate ER Tablets (n=228) and the other group receiving a placebo (n=218).*

FDA Label Image

Fesoterodine-str (Fesoterodine Str)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.